Trial Profile
A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Brimonidine/dorzolamide/timolol (Primary) ; Brimonidine; Dorzolamide; Timolol
- Indications Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms PRO-122LATAM
- Sponsors Laboratorios Sophia
- 05 Dec 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 05 Dec 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 27 Dec 2022 Planned End Date changed from 30 Sep 2022 to 30 Jun 2023.